Display options
Cite
Mehta N, Lyon JG, Patil K, et al. Bacterial Carriers for Glioblastoma Therapy. Mol Ther Oncolytics. 2016;4:1-17doi: 10.1016/j.omto.2016.12.003.
Mehta, N., Lyon, J. G., Patil, K., Mokarram, N., Kim, C., & Bellamkonda, R. V. (2017). Bacterial Carriers for Glioblastoma Therapy. Molecular therapy oncolytics, 41-17. https://doi.org/10.1016/j.omto.2016.12.003
Mehta, Nalini, et al. "Bacterial Carriers for Glioblastoma Therapy." Molecular therapy oncolytics vol. 4 (2017): 1-17. doi: https://doi.org/10.1016/j.omto.2016.12.003
Mehta N, Lyon JG, Patil K, Mokarram N, Kim C, Bellamkonda RV. Bacterial Carriers for Glioblastoma Therapy. Mol Ther Oncolytics. 2016 Dec 14;4:1-17. doi: 10.1016/j.omto.2016.12.003. eCollection 2017 Mar 17. PMID: 28345020; PMCID: PMC5363759.
Copy Download .nbib Format: NLM
Share it on

Mol Ther Oncolytics. 2016 Dec 14;4:1-17. doi: 10.1016/j.omto.2016.12.003. eCollection 2017 Mar 17.

Bacterial Carriers for Glioblastoma Therapy.

Molecular therapy oncolytics

Nalini Mehta, Johnathan G Lyon, Ketki Patil, Nassir Mokarram, Christine Kim, Ravi V Bellamkonda

Affiliations

  1. Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory School of Medicine, UA Whitaker Building, 313 Ferst Drive, Atlanta, GA 30332, USA.
  2. Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory School of Medicine, UA Whitaker Building, 313 Ferst Drive, Atlanta, GA 30332, USA; Department of Biomedical Engineering, Pratt School of Engineering, Duke University, 101 Science Drive, Durham, NC 27708-0271, USA.
  3. Department of Biomedical Engineering, Pratt School of Engineering, Duke University, 101 Science Drive, Durham, NC 27708-0271, USA.

PMID: 28345020 PMCID: PMC5363759 DOI: 10.1016/j.omto.2016.12.003

Abstract

Treatment of aggressive glioblastoma brain tumors is challenging, largely due to diffusion barriers preventing efficient drug dosing to tumors. To overcome these barriers, bacterial carriers that are actively motile and programmed to migrate and localize to tumor zones were designed. These carriers can induce apoptosis via hypoxia-controlled expression of a tumor suppressor protein p53 and a pro-apoptotic drug, Azurin. In a xenograft model of human glioblastoma in rats, bacterial carrier therapy conferred a significant survival benefit with 19% overall long-term survival of >100 days in treated animals relative to a median survival of 26 days in control untreated animals. Histological and proteomic analyses were performed to elucidate the safety and efficacy of these carriers, showing an absence of systemic toxicity and a restored neural environment in treated responders. In the treated non-responders, proteomic analysis revealed competing mechanisms of pro-apoptotic and drug-resistant activity. This bacterial carrier opens a versatile avenue to overcome diffusion barriers in glioblastoma by virtue of its active motility in extracellular space and can lead to tailored therapies via tumor-specific expression of tumoricidal proteins.

Keywords: Azurin; RNU rats; Salmonella typhimurium; VNP 20009; bacteria; brain cancer; drug delivery; glioblastoma; p53; tumor targeting

References

  1. Cancer Res. 1994 Jun 15;54(12):3131-5 - PubMed
  2. Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 - PubMed
  3. Biochemistry. 2007 Feb 20;46(7):1799-810 - PubMed
  4. Oncol Res. 2000;12(3):127-35 - PubMed
  5. Neuro Oncol. 2015 Mar;17 Suppl 2:ii3-ii8 - PubMed
  6. PLoS One. 2008 Jul 09;3(7):e2599 - PubMed
  7. Acta Biochim Pol. 2013;60(3):285-97 - PubMed
  8. Cancer Res. 2000 Dec 15;60(24):6788-93 - PubMed
  9. Cancer Res. 1994 Apr 15;54(8):2095-7 - PubMed
  10. Nat Nanotechnol. 2007 Dec;2(12):751-60 - PubMed
  11. ISRN Neurol. 2012;2012:642345 - PubMed
  12. Science. 2000 May 12;288(5468):1053-8 - PubMed
  13. Front Oncol. 2013 Nov 18;3:278 - PubMed
  14. PLoS One. 2010 Nov 15;5(11):e13984 - PubMed
  15. Gene Ther. 2000 Dec;7(24):2071-9 - PubMed
  16. Cancer Res. 2008 Jun 15;68(12):4827-32 - PubMed
  17. Cell Death Differ. 2006 Jun;13(6):921-6 - PubMed
  18. Mol Cell. 2001 Mar;7(3):683-94 - PubMed
  19. Chem Commun (Camb). 2015 Feb 18;51(14):2756-67 - PubMed
  20. J Biol Chem. 1997 Apr 18;272(16):10353-60 - PubMed
  21. Drug Metab Dispos. 2013 Jan;41(1):33-9 - PubMed
  22. Nature. 1984 Mar 8-14;308(5955):199-201 - PubMed
  23. Nucleic Acids Res. 2006 Jan 1;34(Database issue):D535-9 - PubMed
  24. Int J Microbiol. 2016;2016:5678702 - PubMed
  25. Genome Res. 2003 Nov;13(11):2498-504 - PubMed
  26. Br J Cancer. 2013 Mar 19;108(5):1061-70 - PubMed
  27. J Control Release. 2012 Dec 10;164(2):115-24 - PubMed
  28. J Cell Biochem. 2004 Nov 15;93(5):878-86 - PubMed
  29. Nucleic Acids Res. 2012 Apr;40(7):2984-94 - PubMed
  30. Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):4009-14 - PubMed
  31. ACS Nano. 2015 Jun 23;9(6):5725-40 - PubMed
  32. Cancer Res. 2012 Nov 1;72(21):5441-7 - PubMed
  33. Neuro Oncol. 2015 Oct;17 (10 ):1322-32 - PubMed
  34. Biochem Biophys Res Commun. 2003 May 9;304(3):455-61 - PubMed
  35. Cancer Res. 1997 Oct 15;57(20):4537-44 - PubMed
  36. Biochim Biophys Acta. 2007 Aug;1770(8):1259-65 - PubMed
  37. Nucleic Acids Res. 2016 Jan 4;44(D1):D457-62 - PubMed
  38. PLoS One. 2012;7(5):e37297 - PubMed
  39. Nat Rev Clin Oncol. 2010 Nov;7(11):653-64 - PubMed
  40. Neurosurgery. 2005 Jun;56(6):1243-52; discussion 1252-3 - PubMed
  41. Nat Rev Cancer. 2013 Oct;13(10):714-26 - PubMed
  42. Cell Cycle. 2006 Aug;5(15):1633-41 - PubMed
  43. Nat Biotechnol. 1999 Jan;17(1):37-41 - PubMed
  44. Cancer Res. 1996 Jun 1;56(11):2649-54 - PubMed
  45. J Clin Oncol. 2002 Jan 1;20(1):142-52 - PubMed
  46. Neuropathology. 2005 Mar;25(1):1-7 - PubMed
  47. Pathophysiology. 2016 Jun;23(2):61-6 - PubMed
  48. J Natl Cancer Inst. 1997 Jul 16;89(14):1036-44 - PubMed
  49. Mini Rev Med Chem. 2003 May;3(3):257-70 - PubMed
  50. Cell. 1995 Jan 27;80(2):293-9 - PubMed
  51. Nano Today. 2012 Dec 1;7(6):606-618 - PubMed
  52. Mol Cell Proteomics. 2008 Dec;7(12):2373-85 - PubMed
  53. Nat Biotechnol. 2007 Oct;25(10):1165-70 - PubMed
  54. Mol Cancer Res. 2009 Jul;7(7):989-99 - PubMed
  55. Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14098-103 - PubMed
  56. J Neurooncol. 2012 Apr;107(2):359-64 - PubMed
  57. Proc Natl Acad Sci U S A. 2006 Jul 18;103(29):11003-8 - PubMed
  58. Nucleic Acids Res. 2011 Jul;39(Web Server issue):W307-15 - PubMed
  59. Methods Mol Med. 2004;90:47-60 - PubMed
  60. Hum Mutat. 2005 Jan;25(1):6-17 - PubMed
  61. Chem Rev. 2015 Oct 14;115(19):11147-90 - PubMed
  62. Curr Neuropharmacol. 2012 Mar;10(1):72-9 - PubMed
  63. Neurochem Res. 2012 Jun;37(6):1192-200 - PubMed
  64. Hum Gene Ther. 2005 Jun;16(6):685-98 - PubMed
  65. Mol Cell Biol. 1997 Nov;17(11):6330-8 - PubMed
  66. Methods Mol Biol. 2009;493:191-213 - PubMed
  67. Mol Microbiol. 1998 Jul;29(2):571-9 - PubMed
  68. Cancer Sci. 2012 Feb;103(2):325-33 - PubMed
  69. Bacteriol Rev. 1960 Mar;24(1):50-66 - PubMed
  70. Anticancer Res. 2006 Nov-Dec;26(6C):4633-9 - PubMed
  71. Clin Transl Sci. 2009 Jun;2(3):199-205 - PubMed
  72. J Bacteriol. 1992 Feb;174(3):702-10 - PubMed
  73. Biochem Biophys Res Commun. 2003 May 9;304(3):437-44 - PubMed
  74. Bioengineered. 2014 Jul-Aug;5(4):234-42 - PubMed
  75. J Immunother. 2002 May-Jun;25(3):218-25 - PubMed

Publication Types

Grant support